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http://dxObjectives: New-onset aortic insufficiency (AI) can be encountered after instituting mechanical circulatory
support and seems more common and severe with continuous flow (CF) left ventricular assist devices (LVADs)
compared with pulsatile devices. Treatment algorithms for de novo, post-LVAD AI have not been well defined.
In the present report, we have described 6 patients who underwent aortic valve surgery for new-onset post-
LVAD AI.
Methods: From 2005 to 2011, 271 patients underwent LVAD implantation. Of these LVADs, 225 were CF
devices (203 HeartMate II devices, Thoratec Corp, Pleasanton, Calif; and 22 HVAD devices, HeartWare Intl,
Inc, Framingham, Mass). The patients were examined for new-onset severe AI requiring surgical intervention.
Results: During follow-up, 6 CF LVAD patients developed new, severe AI that was accompanied by heart
failure. After medical therapy had failed, 4 patients underwent redo sternotomy for aortic valve procedures
(1 bioprosthetic valve replacement, 1 Dacron patch closure, and 2 aortic valve repairs), and 2 patients underwent
transcatheter aortic valve procedure, with 1 requiring revision by open surgery for aortic valve replacement. Of
the 6 patients, 5 experienced significant improvement in functional capacity and symptoms. One patient died
postoperatively secondary to multiorgan failure and sepsis.
Conclusions: Surgical treatment of post-LVAD AI with aortic valve oversewing or leaflet repair or by biopros-
thetic aortic valve replacement is effective at restoring functional capacity for CF LVAD patients who develop
symptomatic, severe AI and can be performed safely with good results. Various transcatheter approaches to
these difficult problems are also available and offer less invasive alternatives to conventional surgery. (J Thorac
Cardiovasc Surg 2013;146:1247-52)A shortage of donor hearts for transplantation and recent
improvements in mechanical circulatory support technolo-
gies have substantially increased the enthusiasm for implan-
tation of left ventricular assist devices (LVADs).1 Although
the long-term results with continuous flow (CF) LVAD ther-
apy have been superior to those with pulsatile devices,2
some difficulties previously encountered with pulsatile
devices remain problematic with CF devices. For example,
native heart valve pathologic entities such as significant
mitral stenosis, tricuspid regurgitation, and aortic insuffi-
ciency (AI) can prevent restoration of normal hemodynam-
ics with LVAD support. Therefore, concomitant valvular
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XIn addition, it has been previously recognized that new-
onset AI is frequently encountered during prolonged
LVAD support, just as was first reported with pulsatile
LVADs.4-6 The development of new, significant AI
subsequent to instituting CF LVAD therapy has now been
reported.7-9 However, recent studies have suggested that
CF LVAD support might be associated with more rapid
progression of AI than that with pulsatile devices.10-12
Furthermore, at least 1 study has correlated de novo AI
with worse long-term outcomes after LVAD support.12
Despite increasing awareness of the complications associ-
ated with AI during LVAD support, the treatment strategies
for these patients have not been well defined. Specifically,
given the increased risks accompanying reoperation and
the inherent heterogeneity in the underlying valvular
pathologic features, it is uncertain when surgical correction
should be undertaken and what technique should be used to
correct AI in this unique patient population. Certainly, the
severity of valvular insufficiency, clinical status (symptoms
of heart failure), and previous aortic valve surgery will
influence the clinical decisions in this challenging popula-
tion. To highlight the importance of these issues, we
have described 6 cases (5 HeartMate II, Thoratec Corp,
Pleasanton, Calif; and 1 HVAD, HeartWare Intl, Inc,
Framingham, Mass) of surgical correction of AI after CF
LVAD implantation.diovascular Surgery c Volume 146, Number 5 1247
Abbreviations and Acronyms
AI ¼ aortic insufficiency
AVR ¼ aortic valve replacement
CF ¼ continuous flow
LVAD ¼ left ventricular assist device
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XMETHODS
After local institutional review board approval, we reviewed the records
of 271 patients with end-stage heart failure who had undergone LVAD
implantation at a single institution (2005-2011). Of the LVAD devices,
225 were CF LVADs (203 HeartMate II and 22 HVADs). At LVAD inser-
tion, all patients underwent transesophageal echocardiography to evaluate
the native cardiac valves and exclude intracardiac shunts. Routine patient
follow-up at our institution consisted of transthoracic echocardiography
every 6 months. During transthoracic echocardiography, attention was
given to AI, with medical treatment of systemic blood pressure reduction
used for any AI that is moderate or less. During this period, 5 patients
underwent a concomitant aortic valve procedure at LVAD implantation
for significant AI. Subsequently, 6 patients developed new, significant AI
in the postoperative period requiring surgical intervention (Table 1), and
we present these cases. The surgical care in each case was specifically
tailored to the pathologic features present and overall patient health.RESULTS
Case 1
A 75-year-old man underwent HeartMate II LVAD
for ischemic cardiomyopathy as destination therapy. At
6 months postoperatively, he returned with new-onset,
severe AI and increased pump power and pulsatility index.
Percutaneous repair with an 18-mm Amplatzer PI Muscular
ventricular septal defect occluder (AGA Medical, Ply-
mouth, Minn) positioned at the level of the aortic annulus
(Figure 1, A) was initially attempted; however, the device
migrated into the left ventricle, prompting concerns for
LVAD inflow cannula interference and causing severe AI
(Figure 1, B). The patient underwent urgent redo sternot-
omy for ventricular septal defect occluder retrieval and
aortic valvuloplasty due to incomplete central coaptation
of central leaflets, using the technique described by Park
et al.13 However, significant residual AI was identified after
separation from cardiopulmonary bypass, and subsequent
bioprosthetic aortic valve replacement (AVR) was per-
formed with an uneventful recovery.Case 2
A 70-year-old man with nonischemic cardiomyopathy
secondary to rheumatic heart disease and remote biopros-
thetic AVR underwent destination LVAD implantation
with a HeartMate II. Four years later, he presented with re-
fractory heart failure and severe bioprosthetic AI. Because
of his poor underlying medical condition, he underwent
off-label, transcatheter insertion of a Melody Transcath-
eter Pulmonary Valve (Medtronic, Minneapolis, Minn;
Figure 2) within the previous bioprosthetic valve. Although1248 The Journal of Thoracic and Cardiovascular Surresidual, mild AI was present at the conclusion of the pro-
cedure, the patient was discharged from the hospital and
experienced functional improvement.
Case 3
A 73-year-old woman with suspected doxorubicin-
induced cardiomyopathy underwent HeartMate II insertion
as destination therapy. Trivial AI was evident preopera-
tively (Figure 3); however, 1 month later, she experienced
heart failure symptoms, progressing to cardiogenic shock.
Echocardiography revealed new-onset severe AI and severe
tricuspid insufficiency. Despite aggressive medical therapy,
the patient remained unstable and underwent emergent redo
sternotomy. Significant prolapse of the noncoronary cusp
was noted after aortotomy, bioprosthetic AVR, and tricuspid
valve annuloplasty was performed. Notably, the patient
also had left ventricular and intrapump thrombus, and
a pump exchangewas performed. Unfortunately, the patient
developed sepsis and renal failure and died 6 weeks later.
Case 4
A 67-year-old man underwent HeartMate II LVAD inser-
tion for ischemic cardiomyopathy. Approximately 1 year
later, he developed new, recurrent heart failure symptoms,
with echocardiographic findings of new severe AI with
a concurrent increased pump power and pulsatility index.
He underwent redo sternotomy with cardiopulmonary
bypass. Marked thickening of all 3 leaflets and commissural
fusion was noted. Consequently, Dacron patch closure
of the aortic valve was performed. The patient recovered
well, with functional improvement despite significant
preoperative debilitation.
Case 5
A 67-year-old woman underwent destination therapy
with an HVAD for ischemic cardiomyopathy. Four months
later, she presented with recurrent heart failure and new-
onset, severe AI. Redo sternotomy revealed scarring and
retraction of the left coronary cusp. Several sutures were
placed through the nodules of Arantius to elevate the
retracted cusp to the level of the non- and right coronary
cusps, resolving the valvular insufficiency. The patient
did well postoperatively and demonstrated functional
improvement.
Case 6
A 41-year-old woman presented with acute myocardial
infarction and underwent emergency coronary artery by-
pass grafting. She developed postcardiotomy shock and
required extracorporeal membrane oxygenation, with sub-
sequent urgent placement of a HeartMate II LVAD. Two
years later, she presented with severe heart failure and
hemolysis. Echocardiography revealed newly diagnosed
moderate-to-severe AI. After medical management failed,gery c November 2013
TABLE 1. Patient demographics and characteristics
Pt. no. Age (y)
Pathologic
features LVAD type Pre-LVAD TEE
Interval from VAD
implantation to severe AI
presentation (mo) Procedure performed
1 75 ICM HMII No AI 6 Open AVR
2 70 NICM HMII Bioprosthetic aortic valve,
trivial AI
48 Percutaneous valve-in-valve
3 73 NICM HMII Trivial AI 1 Open AVR; VAD pump exchange
4 67 ICM HMII Mild AI 12 Open Dacron patch closure
5 67 ICM HVAD Trace AI 4 Open Park sutures
6 43 ICM HMII No AI 28 Open Park sutures; VAD pump
exchange
Pt. no., Patient number; LVAD, left ventricular assist device; TEE, transesophageal echocardiography; ICM, ischemic cardiomyopathy; HMII, HeartMate II assist device
(Thoratec Corp, Pleasanton, Calif); AI, aortic insufficiency; AVR, aortic valve replacement; NICM, nonischemic cardiomyopathy; HVAD, HeartWare Intl, Inc assist device
(Framingham, Mass); VAD, ventricular assist device.
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nary cusp with commissural fusion was noted. Valve repair
with interrupted polypropylene sutures, to elevate the right
coronary cusp to the level of the left and noncoronary cusps
was performed. Because of the complicating history of he-
molysis with the potential for pump thrombosis, the patient
also underwent LVAD pump replacement. The patient did
well postoperatively and was discharged to home.
Overall, surgical correction of AI was accomplished
using several different techniques, which were individually
selected according to unique features of the case. In all
6 cases, echocardiography demonstrated correction of se-
vere AI, and, with the exception of 1 patient, all experienced
significant functional recovery. Two transcatheter treat-
ments were used, and in 1 of the cases, a catheter-based,
valve-in-valve strategy was successful.
DISCUSSION
For patients with end-stage heart failure, CF LVAD
support as a bridge to transplantation or as destination ther-
apy has been shown to improve survival, functional status,
quality of life, and exercise capacity.2,14-16 Furthermore,
compared with pulsatile devices, CF LVADs have greater
durability.2,16 Given the extended survival of patients
supported with CF LVAD therapy, previously uncommon
disorders are now being seen with increasing
frequency.17,18 For example, CF LVAD therapy has been
implicated in the development of acquired AI, acquired
von Willebrand syndrome with mucosal bleeding, and
other issues associated with the physiology of nonpulsatile
blood flow.17,19 As Frazier14 has suggested, clinicians treat-
ing patients with an CF LVADmust be adept at investigating
and managing these relatively new disorders.
In the setting of LVAD therapy, AI leads to blood volume
recirculation, inadequate left ventricular unloading, de-
creased systemic perfusion, and increased LVAD pump
work.20,21 These effects essentially produce clinical heart
failure with progressive dyspnea and reduced functional
status, and 1 study demonstrated patients developing AIThe Journal of Thoracic and Carafter LVAD therapy had decreased survival.12 The propen-
sity for developing AI during LVAD support appears to
correlate with the duration of LVAD support,10 and the pro-
gression of AI might be greater with CF devices than with
pulsatile devices.10-12 Furthermore, increased CF LVAD
pump speeds result in greater left ventricular unloading
and reduces pulsatility, creating near constant retrograde
forces at the level of the sinuses of Valsalva and loss of
normal systolic valvular relaxation.17,22,23 Progression
of postoperative AI might correlate with the infrequency
of aortic valve opening.10-13 A previous study in a nearly
identical cohort of patients at our institution demonstrated
that 11% of patients progressed to moderate or severe AI
after LVAD implantation. Of these, all patients with
moderate AI were able to be treated medically, but those
with severe AI required surgical intervention.9 Regardless
of the specific contributing factors, partial fusion and
restriction of the aortic valve leaflets have been described
as the anatomic changes during CF LVAD therapy that
lead to AI.21-23 At least 4 of our 6 patients displayed these
pathologic changes. It is unclear whether these pathologic
changes affect the bioprosthetic valves. It is noteworthy
that in patient 2, the pre-existing bioprosthetic valve did
not deteriorate within the same period as the native valves
of the other 4 patients in our series.
The primary nonsurgical treatment of de novo AI in CF
LVAD patients has been treatment of hypertension to
reduce left ventricular and LVAD afterload and has been
our standard therapy in this setting.9,24,25 In all 6 patients
in the present series, medical therapy was attempted,
including afterload reduction, diuretics, and inotropes. In
all 6 patients, these conservative measures failed to
stabilize the patient and resolve the symptoms. Therefore,
conservative measures are likely to be ineffective in the
setting of severe AI and CF LVAD support. Notably, 1 of
the 6 patients (patient 3) had an initial delay in surgical
intervention and subsequently became quite unstable,
providing an additional argument for expeditious surgical
intervention.diovascular Surgery c Volume 146, Number 5 1249
FIGURE 2. A, A transcatheter approach by way of the femoral artery was
used to insert a bovine jugular vein valve (Melody transcatheter pulmonary
valve) within the existing, regurgitant aortic bioprosthesis as valve-in-valve
therapy for severe aortic insufficiency. The undeployed Melody valve can
be seen within the aortic bioprosthesis. B, Postdeployment image of the
Melody valve within the bioprosthesis, with mild, residual aortic insuffi-
ciency present.
FIGURE 1. A, An 18-mm AMPLATZER PI Muscular ventricular septal
defect Occluder was initially used to treat aortic regurgitation presenting
6 months after left ventricular assist device implantation. The ventricular
septal defect occluder can be seen inferior to the pigtail catheter (dashed
arrow). B, Despite the initial success, the ventricular septal defect occluder
had migrated several days later (seen on echocardiography) and was asso-
ciated with recurrent severe aortic insufficiency, which prompted open
aortic valve replacement.
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a major intervention with risks for right ventricular damage
or failure and hemorrhage. Nevertheless, for patients who
develop severe AI, open surgical correction might provide
a survival advantage, given the lack of proven, successful
alternative treatments. This approach of oversewing the
aortic valve with a modified Park stitch represents our cur-
rent practice guidelines in the setting of de novo severe AI.
In 1 single-institution experience, long-term survival was
shown to be significantly better among LVAD patients
who underwent AI repair compared with LVAD patients1250 The Journal of Thoracic and Cardiovascular Surwith uncorrected AI.7 In the present case series, 4 of the
5 patients survived redo sternotomy and experienced func-
tional recovery. The 1 patient who died postoperatively had
undergone surgery after a significant delay and had renal
failure before the attempted valve procedure. Again, these
examples reiterate that earlier, more elective surgical inter-
ventions could yield better outcomes, and delaying
intervention to the point of end organ dysfunction will
predictably yield negative outcomes.gery c November 2013
FIGURE 3. Transesophageal echocardiogram demonstrating trivial aortic
insufficiency at HeartMate II left ventricular assist device implantation
with grading based on the width of the regurgitant jet vena contracta.14
At present, it is unclear whether nonsignificant aortic insufficiency predis-
poses the patient to worsening valvular regurgitation after left ventricular
assist device implantation.
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in the postoperative setting, particularly relatively soon
after surgery, is that unrecognized, significant AI was pres-
ent preoperatively. However, on examining the patients we
have presented, specifically patients 3, 4, and 5, in whom
aortic valve pathologic features were noted at the subse-
quent operation, the intraoperative transesophageal echo-
cardiography at LVAD implantation revealed trace, mild,
and trace AI, respectively. It has been our clinical practice
to perform an aortic valve intervention in the setting of AI
that is greater than mild at LVAD implantation. Because
none of these patients met this criterion, no aortic valve pro-
cedure was initially pursued. Examination of a similar
patient population by our group revealed that preimplant
AI was not a significant predictor of progression of AI after
implantation.9 A review of the patients after the described
interventions indicated that patients who underwent bio-
prosthetic AVR have prostheses that remain closed during
most of the cardiac cycle, as shown by echocardiography,
without any evidence of premature structural deterioration.
Also, the 1 patient with bioprosthetic AVR before LVAD
implantation had had the longest duration between im-
plantation and the development of severe AI (4 years),
potentially indicating that these prostheses are relatively
durable when subjected to CF.
A transcatheter strategy to correct severe AI in these
patients would help avoid the risks associatedwith redo ster-
notomy. Innovative approaches incorporating transcatheter
aortic valve procedures during LVAD therapy have beenThe Journal of Thoracic and Carused successfully elsewhere.26,27 In 2 of our 6 cases,
a transcatheter treatment was attempted: 1 AMPLATZER
VSD occluder was deployed, and 1 bovine jugular
vein valve was inserted within an existing bioprosthetic
aortic valve. However, the AMPLATZER occluder
migrated, and we are aware of 1 other case at another
institution in which device migration occurred (Laura
Janney and Robert Adamson, personal communication,
2013). In our case, open surgery was required, but the
patient remained stable and did not experience the need
for emergency surgery. The use of a transcatheter Melody
valve in 1 case was successful at reducing AI and
achieving functional improvement. However, in that case,
the patient had a previous bioprosthetic AVR, and the rigid
struts provided a good landing zone and seating area for
the transcatheter valve. The Melody valve also has sizing
limitations, with the largest available prosthesis 22 mm
in diameter. The recently approved Sapien transcatheter
aortic valve (Edwards Lifesciences, Irvine, Calif) is
available in 23-mm and 26-mm diameters, also limiting
application to smaller annular diameters, and the device is
not yet widely available. Finally, the CoreValve device
(Medtronic) has 26-, 29-, and 31-mm sizes, but the valve
remains in clinical trials. Thus, the CoreValve is not avail-
able for off-label applications such as treatment of post-
LVADAI. Importantly, neither the Sapien nor the CoreValve
device was designed to treat AI, but both have been used for
this application on a limited basis outside of the United
States. Treatment of AI using transcatheter methods appears
more challenging than treating calcific aortic stenosis,
because the absence of valvular calcification obscures the
precise identity of the aortic annular landing zones. How-
ever, we speculate that this technique will almost certainly
become the treatment of choice for significant post-LVAD
AI once additional experience has been gained.
Overall, these results have indicated that the presence of
severe AI after LVAD implantation, particularly in the setting
of symptoms of heart failure,warrants intervention.Also,with
appropriate, early treatment, patients have the potential for
functional recovery. In this scenario, our typical approach
would consist of aortic valve repairwith amodifiedPark stitch;
however, certain valvular characteristics, such as heavily
calcified leaflets, might preclude this approach, necessitating
AVR. Additionally, in cases in which redo sternotomy proves
to be risk prohibitive, transcatheter interventions provide an
alternativewith the potential for functional recovery.Although
we have demonstrated good results with these interventions,
the small number of repair or replacement procedures preclude
comment on the advantages of 1 technique over another, and
additional investigation is warranted.
CONCLUSIONS
Surgical treatment of post-LVADAI by aortic valve repair,
valve orifice oversewing, or AVR can be effective at restoringdiovascular Surgery c Volume 146, Number 5 1251
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Xfunctional capacity forCFLVADpatientswhodevelop symp-
tomatic, severe AI. Transcatheter approaches to these diffi-
cult scenarios offer less invasive options in appropriate cases.References
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